Platelet function testing and genotyping may help tailor antiplatelet therapy in acute coronary syndrome, but heterogeneity and practical challenges limit their routine use.
Does platelet function testing and genotyping improve outcomes in patients with acute coronary syndrome?
While platelet function testing and genotyping show promise for personalizing antiplatelet therapy in ACS, practical challenges and heterogeneity currently limit their routine clinical application.
Absolute Event Rate: 0% vs 0%
Existing evidence shows that PFT and genotyping may provide significant findings for tailoring antiplatelet therapy in ACS. However the heterogeneity and practical challenges limit their routine use. Further, well-designed outcome driven studies and standardised protocols are required to define their role in precision guided therapy for ACS management.
Rebello et al. (Mon,) reported a other. Platelet function testing and genotyping may help tailor antiplatelet therapy in acute coronary syndrome, but heterogeneity and practical challenges limit their routine use.